Abbott Laboratories $ABT Shares Purchased by Mission Wealth Management LP

Key Points

• Mission Wealth Management LP more than doubled its Abbott Laboratories stake in the second quarter, acquiring 24,487 additional shares for a total of 48,849 shares valued at approximately $4.43 million. Institutional investors collectively own 75.18% of the company.
• Analysts maintain a generally positive outlook, with Abbott receiving a consensus “Moderate Buy” rating and an average price target of $118.67, despite several recent target-price cuts.
• Abbott exceeded quarterly earnings and revenue expectations, reporting $1.31 in EPS and $12.59 billion in revenue, while revenue rose 13% year over year. The company also paid a quarterly dividend of $0.63 per share, equivalent to a 2.3% annualized yield.

Mission Wealth Management LP boosted its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 100.5% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 48,849 shares of the healthcare product maker's stock after acquiring an additional 24,487 shares during the period. Mission Wealth Management LP's holdings in Abbott Laboratories were worth $4,433,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in ABT. Brighton Jones LLC boosted its position in Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after purchasing an additional 4,755 shares during the period. Sivia Capital Partners LLC increased its position in Abbott Laboratories by 3.5% in the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker's stock worth $648,000 after buying an additional 162 shares during the period. United Bank lifted its stake in Abbott Laboratories by 7.4% in the second quarter. United Bank now owns 29,004 shares of the healthcare product maker's stock valued at $3,945,000 after buying an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC boosted its holdings in shares of Abbott Laboratories by 13.6% during the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker's stock valued at $1,618,000 after acquiring an additional 1,428 shares during the period. Finally, Canada Pension Plan Investment Board grew its position in shares of Abbott Laboratories by 25.6% during the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker's stock worth $195,267,000 after acquiring an additional 292,547 shares during the last quarter. 75.18% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Robert W. Baird assumed coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They issued an "outperform" rating and a $121.00 price objective on the stock. Barclays decreased their target price on shares of Abbott Laboratories from $144.00 to $143.00 and set an "overweight" rating for the company in a research report on Monday, April 20th. UBS Group cut their price target on Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating on the stock in a report on Tuesday, July 28th. Weiss Ratings upgraded Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Thursday, August 6th. Finally, Leerink Partners decreased their price objective on Abbott Laboratories from $119.00 to $106.00 and set a "market perform" rating for the company in a report on Tuesday, April 21st. Three analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $118.67.

Abbott Laboratories Stock Performance

Shares of ABT opened at $110.68 on Tuesday. The firm has a market capitalization of $191.52 billion, a PE ratio of 35.82, a P/E/G ratio of 2.15 and a beta of 0.59. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The firm has a 50-day moving average price of $98.08 and a 200 day moving average price of $99.79. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping analysts' consensus estimates of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. Abbott Laboratories's revenue was up 13.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories's dividend payout ratio is 81.55%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source